Hemi-ablative low-dose-rate prostate brachytherapy for unilateral localised prostate cancer
Autor: | Robert Laing, Santiago Uribe-Lewis, Claire Deering, Alex Horton, Donna Higgins, S. Khaksar, A. Franklin, Jennifer Uribe, Carla Perna, Melanie Cunningham, Stephen M. Langley |
---|---|
Rok vydání: | 2019 |
Předmět: |
medicine.medical_specialty
business.industry Urology medicine.medical_treatment Urinary system 030232 urology & nephrology medicine.disease 03 medical and health sciences Prostate cancer 0302 clinical medicine Urethra medicine.anatomical_structure 030220 oncology & carcinogenesis Toxicity medicine Potency Implant Prospective cohort study business Prostate brachytherapy |
Zdroj: | BJU International. 125:383-390 |
ISSN: | 1464-4096 |
Popis: | OBJECTIVES To report clinical outcomes of the Hemi-Ablative Prostate Brachytherapy (HAPpy) trial evaluating treatment-related toxicity and effectiveness of hemi-gland (HG) low-dose-rate (LDR) prostate brachytherapy as a focal approach to control unilateral localised prostate cancer. PATIENTS AND METHODS Single institution phase IIS pilot study of patients treated with focal 4D Brachytherapy™ (BXTAccelyon, Burnham, Buckinghamshire, UK). The primary outcome was patient-reported toxicity 24 months after implant. The secondary outcome was assessment of disease control. Outcomes in HG patients were compared to whole-gland (WG) controls obtained from our prospective cohort registry by negative binomial and linear regression models. RESULTS Pre-treatment demography was similar between the 30 HG patients and 362 WG controls. Post-implant dosimetry was similar for the prostate gland target volumes and significantly reduced for the urethra and bowel in HG patients relative to WG controls, but this did not translate into a difference in post-implant mean symptom scores between the two groups. Nevertheless, the change in score from baseline indicated that the impact on pre-treatment symptom status was less after HG implants. Only HG patients showed a return to baseline urinary scores as early as 12 months. Sexual potency was conserved in 73% and 67% of HG and WG patients, respectively (P = 0.84). Post-implant prostate-specific antigen (PSA) kinetics revealed that baseline PSA was reduced at 24 months by 78% and 88% in HG and WG patients, respectively (P |
Databáze: | OpenAIRE |
Externí odkaz: |